CNS stimulant. Targets monoamine transporters to elevate synaptic levels of noradrenalin, dopamine and serotonin.
|Storage||Desiccate at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 184.25. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||5.43 mL||27.14 mL||54.27 mL|
|5 mM||1.09 mL||5.43 mL||10.85 mL|
|10 mM||0.54 mL||2.71 mL||5.43 mL|
|50 mM||0.11 mL||0.54 mL||1.09 mL|
References are publications that support the products' biological activity.
Barr et al (1999) Effects of withdrawal from an escalating dose schedule of d-Amphetamine on sexual behavior in the male rat. Pharmacol.Biochem.Behav. 64 597 PMID: 10548277
Cartmell et al (1999) The metabotropic glutamate 2/3 receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus d-Amphetamine motor behaviors in rats. J.Pharmacol.Exp.Ther. 291 161 PMID: 10490900
Rothman and Baumann (2006) Balance between dopamine and serotonin release modulates behavioral effects of Amphetamine-type drugs. Ann.N.Y.Acad.Sci. 1074 245 PMID: 17105921
If you know of a relevant reference for D-Amphetamine sulfate, please let us know.
View Related Products by Target
Keywords: D-Amphetamine sulfate, supplier, Induces, 5-HT, dopamine, noradrenaline, release, Serotonin, 5-Hydroxytryptamine, amphetamine, Dextroamphetamine, sulfate, Dopaminergic-Related, Adrenergic, Related, Compounds, 5-HT-Related, 5-HT3, Receptors, Dopaminergic-Related, Tocris Bioscience
4 Citations for D-Amphetamine sulfate
Citations are publications that use Tocris products. Selected citations for D-Amphetamine sulfate include:
Czysz et al (2015) Lateral diffusion of Gαs in the plasma membrane is decreased after chronic but not acute antidepressant treatment: role of lipid raft and non-raft membrane microdomains. PLoS One 40 766 PMID: 25249058
Soda et al (2013) DISC1-ATF4 transcriptional repression complex: dual regulation of the cAMP-PDE4 cascade by DISC1. Mol Psychiatry 18 898 PMID: 23587879
Rennekamp et al (2016) σ1 receptor ligands control a switch between passive and active threat responses. Nat Chem Biol 12 552 PMID: 27239788
Ribeiro et al (2014) Metabotropic glutamate receptor 5 knockout promotes motor and biochemical alterations in a mouse model of Huntington's disease. Neuropsychopharmacology 23 2030 PMID: 24282028
Do you know of a great paper that uses D-Amphetamine sulfate from Tocris? If so please let us know.
Reviews for D-Amphetamine sulfate
There are currently no reviews for this product. Be the first to review D-Amphetamine sulfate and earn rewards!
Have you used D-Amphetamine sulfate?
Submit a review and receive an Amazon gift card.
$10US/$10CAN/€7/£6 gift card for a review without an image
$25US/$25CAN/€18/£15 gift card for a review with an image
*Offer only valid in the USA / Canada, UK and EuropeSubmit a Review
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Dopamine Receptors Scientific Review
Written by Phillip Strange and revised by Kim Neve in 2013, this review summarizes the history of the dopamine receptors and provides an overview of individual receptor subtype properties, their distribution and identifies ligands which act at each receptor subtype. Compounds available from Tocris are listed.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.